8 January 2024

Frost & Sullivan Analysis Reveals 65% of US Biotechs Struggle to Identify Suitable CRO Partner

Frost & Sullivan Analysis Reveals 65% of US Biotechs Struggle to Identify Suitable CRO Partner

Latest Analysis Reveals 65% of US Biotechs Struggle to Identify Suitable CRO Partner – Affecting Drug Development Schedules & Financial Plans

Avance Clinical, the leading Australian and North American CRO for biotechs announced today that new industry analysis shows 60-65% of US biotechs face challenges identifying the right sized CRO partner that can deliver at every phase of their drug development program. The report found this directly affected clinical programs and budgets.

The report also found that 50% of biotechs engaged with more than one CRO over the course of their clinical program potentially impacting knowledge transfer, timelines and budget.

Fill in the form to download the white paper

Download Whitepaper
Terms and conditions

Related Articles